The Medical Letter on Drugs and Therapeutics
Subscribers: Log in to read full issue.  Not a subscriber?  Subscribe or purchase issue.
A 4-Drug Combination (Viekira Pak) for Hepatitis C

The FDA has approved Viekira Pak (Abbvie), a fixed-dose combination of two new direct-acting antiviral agents (ombitasvir, paritaprevir) with the pharmacologic enhancer ritonavir in one tablet, co-packaged with a third new direct-acting antiviral agent (dasabuvir) in a second tablet, for oral treatment of chronic hepatitis C virus (HCV) genotype 1 infection. Genotype 1 is responsible for 70-80% of HCV infections in the US.

Viekira Pak is the second all-oral, interferon-free, fixed-dose combination for treatment of chronic HCV genotype 1 infection to be approved in the US; it will compete with the fixed-dose combination of sofosbuvir and ledipasvir (Harvoni) for inclusion in the formularies of third-party payers. Neither Harvoni nor Viekira Pak is approved for treatment of infections caused by HCV genotypes 2-6.

DRUGS FOR HCV GENOTYPE 1 INFECTION — Harvoni has ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this issue?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this issue:
Title: Issue 1461
 Downloadable, electronic issue - $45

Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian